84 related articles for article (PubMed ID: 28401189)
1. p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.
Timofeev O; Stiewe T
Mol Cell Oncol; 2017; 4(2):e1288678. PubMed ID: 28401189
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
4. Identifying small molecule probes of ENTPD5 through high throughput screening.
Durst MA; Ratia K; Lavie A
PLoS One; 2019; 14(6):e0210305. PubMed ID: 31242188
[TBL] [Abstract][Full Text] [Related]
5. Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5)-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest.
Read R; Hansen G; Kramer J; Finch R; Li L; Vogel P
Vet Pathol; 2009 May; 46(3):491-504. PubMed ID: 19176496
[TBL] [Abstract][Full Text] [Related]
6. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.
Fang M; Shen Z; Huang S; Zhao L; Chen S; Mak TW; Wang X
Cell; 2010 Nov; 143(5):711-24. PubMed ID: 21074248
[TBL] [Abstract][Full Text] [Related]
7. ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression.
Xue Y; Wu L; Liu Y; Ma Y; Zhang L; Ma X; Yang Y; Chen J
PLoS One; 2015; 10(3):e0120046. PubMed ID: 25794010
[TBL] [Abstract][Full Text] [Related]
8. Identity between the PCPH proto-oncogene and the CD39L4 (ENTPD5) ectonucleoside triphosphate diphosphohydrolase gene.
Páez JG; Recio JA; Rouzaut A; Notario V
Int J Oncol; 2001 Dec; 19(6):1249-54. PubMed ID: 11713596
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 drives invasion by promoting integrin recycling.
Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
[TBL] [Abstract][Full Text] [Related]
11. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?
Hu J; Liu Z; Wang X
Med Hypotheses; 2013 Oct; 81(4):515-20. PubMed ID: 23880140
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.
Gwak H; Kim S; Dhanasekaran DN; Song YS
Cancer Lett; 2016 Feb; 371(2):347-53. PubMed ID: 26704305
[TBL] [Abstract][Full Text] [Related]
13. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
[TBL] [Abstract][Full Text] [Related]
14. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
15. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.
Basu S; Gnanapradeepan K; Barnoud T; Kung CP; Tavecchio M; Scott J; Watters A; Chen Q; Kossenkov AV; Murphy ME
Genes Dev; 2018 Feb; 32(3-4):230-243. PubMed ID: 29463573
[TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.
Walerych D; Pruszko M; Zyla L; Wezyk M; Gaweda-Walerych K; Zylicz A
Oncotarget; 2018 Aug; 9(62):32063-32080. PubMed ID: 30174797
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells.
Ahn JH; Kim TJ; Lee JH; Choi JH
Sci Rep; 2017 Aug; 7(1):9076. PubMed ID: 28831167
[TBL] [Abstract][Full Text] [Related]
19. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
20. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
